SEARCH

SEARCH BY CITATION

References

  • 1
    Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003;289:253444.
  • 2
    LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:23406.
  • 3
    Amarenco P, Labreuche J, Lavallée P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004;35:29029.
  • 4
    Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:126778.
  • 5
    Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average of lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm (ASCOT–LLA): a multicentre randomized controlled trial. Lancet 2003;161:114958.
  • 6
    Lindgren P, Buxton M, Kahan T, et al. Cost-effectiveness of atorvastatin in the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm (ASCOT–LLA). Eur J Cardiovasc Prev Rehabil 2005;12:2936.
  • 7
    Shepherd J. Economics of lipid lowering in primary prevention: lessons from the West of Scotland Coronary Prevention Study. Am J Cardiol 2001;87:1922B.
  • 8
    Prosser LA, Stinnett AA, Goldman PA, et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 2000;132:76979.
  • 9
    Tsevat J, Kuntz KM, Orav EJ, et al. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J 2001;141:72734.
  • 10
    Hay JW, Yu WM, Ashraf T. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease. Pharmacoeconomics 1999;15:4774.
  • 11
    Grover SA, Coupal L, Paquet S, Zowall H. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med 1999;159:593600.
  • 12
    Ganz DA, Kuntz KM, Jacobson GA, Avorn J. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. Ann Intern Med 2000;132: 7807.
  • 13
    Franco OH, Peeters A, Looman CW, Bonneux L. Cost-effectiveness of statins in coronary heart disease. J Epidemiol Community Health 2005;59:92733.
  • 14
    Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:447.
  • 15
    Kramer JM, Hammill B, Anstrom KJ, et al. National evaluation of adherence to beta-blocker therapy for 1-year after acute myocardial infarction in patients with commercial health insurance. Am Heart J 2006; 152:4548.
  • 16
    Cardinal H, Monfared AA, Dorais M, LeLorier J. A comparison between persistence to therapy in ALLHAT and in everyday clinical practice: a generalizability issue. Can J Cardiol 2004;20:41721.
  • 17
    Van Wijk BL, Klungel OH, Heerdink ER, De Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005;23:21017.
  • 18
    Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:45661.
  • 19
    Caspard H, Chan AK, Walker AM. Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. Clin Ther 2005;27:163946.
  • 20
    Perreault S, Blais L, Lamarre D, et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 2005;59:56473.
  • 21
    Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:4627.
  • 22
    Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;161:114752.
  • 23
    Blackburn DF, Dobson RT, Blackburn JL, et al. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol 2005;21:4858.
  • 24
    Gold MR, Slegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
  • 25
    D’Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham Study. Am Heart J 2000;139:27281.
  • 26
    D’Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication. Stroke 1994;25:403.
  • 27
    Hardie K, Hankey GJ, Jamrozik K, et al. Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study. Stroke 2004;35:7315.
  • 28
    Wolf PA, D’Agostino RB, Belanger AK, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991;22:3128.
  • 29
    Centers for Disease Control and Prevention, National Center for Health Statistics. National health and nutrition examination survey data, 2003–2004. Available from: http://www.cdc.gov/nchs/about/major/nhanes/nhanes2003-2004/nhanes03_04.htm[Accessed October 4, 2007.
  • 30
    The North American Menopause Association (NMAS). About menopause, supplement. Available from: http://www.menopause.org/aboutmeno/04A.pdf[Accessed November 12, 2007.
  • 31
    Arias E. United States Life Tables, 2002. National Vital Statistics Reports. Vol 53, no. 6. Hyattsville, MD: National Center for Health Statistics, 2004.
  • 32
    Hoyert DL, Kung HC, Smith BL. Deaths: Preliminary Data for 2003. National Vital Statistics Reports. Vol 53, no. 15. Hyattsville, MD: National Center for Health Statistics, 2005.
  • 33
    Furman MI, Dauerman HL, Goldberg RJ, et al. Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective. J Am Coll Cardiol 2001;37:157180.
  • 34
    Goldberg RJ, McCormick D, Gurwitz JH, et al. Age-related trends in short- and long-term survival after acute myocardial infarction: a 20-year population-based perspective (1975–1995). Am J Cardiol 1998; 82:13117.
  • 35
    Dennis MS, Burn JP, Sandercock PA, et al. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke 1993;24:796800.
  • 36
    Russell MW, Huse DM, Drowns S, et al. Direct medical costs of coronary artery disease in the United States. Am J Cardiol 1998;81:11105.
  • 37
    US Department of Health and Human Services, Centers for Medicare and Medicaid Services. Diagnosis related group weights (2005). Available from: http://www.cms.hhs.gov/MedicareFeeforSvcPartsAB/Downloads/DRGdesc05.pdf[Accessed January 4, 2008.
  • 38
    US Department of Health and Human Services, Centers for Medicare and Medicaid Services. Impact file for prospective payment system. Available from: http://www.cms.hhs.gov/HospitalOutpatientPPS/Downloads/CMS1506FC.pdf[Accessed October 4, 2007.
  • 39
    US Department of Health and Human Services, Centers for Medicare and Medicaid Services. CMS-1428-F(2) published in Federal Register August 11, 2004. Available from: http://www.cms.hhs.gov/AcuteInpatientPPS/Downloads/cms1428f_iv.pdf[Accessed January 20, 2008.
  • 40
    Miller ME, Welch WP. Analysis of Hospital Medical Staff Volume Performance Standards: Technical Report. Washington, DC: The Urban Institute, 1993.
  • 41
    US Department of Health and Human Services, Centers for Medicare and Medicaid Services. National physician fee schedule. Available from: http://www.cms.hhs.gov/PhysicianFeeSched/[Accessed January 4, 2008.
  • 42
    Samsa GP, Bian J, Lipscomb J, Matchar DB. Epidemiology of recurrent cerebral infarction: a medicare claims-based comparison of first and recurrent strokes on 2-year survival and cost. Stroke 1999;30:33849.
  • 43
    Redbook 2006 August Update. Montvale, NJ: Thomson Micromedex, 2006.
  • 44
    US Department of Labor, Bureau of Labor and Statistics. US medical care consumer price index, all urban consumers. CUUR0000SAM. Available from: http://data.bls.gov/cgi-bin/surveymost?cu[Accessed February 4, 2008.
  • 45
    Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT–BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895906.
  • 46
    Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995;15:36990.
  • 47
    Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med 1980;303:103841.
  • 48
    Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:10516.
  • 49
    Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:162330.